AU2016236669B2 - Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof - Google Patents

Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof Download PDF

Info

Publication number
AU2016236669B2
AU2016236669B2 AU2016236669A AU2016236669A AU2016236669B2 AU 2016236669 B2 AU2016236669 B2 AU 2016236669B2 AU 2016236669 A AU2016236669 A AU 2016236669A AU 2016236669 A AU2016236669 A AU 2016236669A AU 2016236669 B2 AU2016236669 B2 AU 2016236669B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
solution
mixture
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016236669A
Other languages
English (en)
Other versions
AU2016236669A1 (en
Inventor
Qingrui SUN
Tianzhi WU
Zusheng XU
Nong Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Yingli Pharmaceutical Co Ltd
Original Assignee
Shanghai Yingli Pharm Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yingli Pharm Co Ltd, Shanghai Yingli Pharmaceutical Co Ltd filed Critical Shanghai Yingli Pharm Co Ltd
Publication of AU2016236669A1 publication Critical patent/AU2016236669A1/en
Application granted granted Critical
Publication of AU2016236669B2 publication Critical patent/AU2016236669B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016236669A 2015-03-24 2016-02-01 Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof Active AU2016236669B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510131828 2015-03-24
CN201510131828.5 2015-03-24
PCT/CN2016/073043 WO2016150255A1 (zh) 2015-03-24 2016-02-01 稠环衍生物、其制备方法、中间体、药物组合物及应用

Publications (2)

Publication Number Publication Date
AU2016236669A1 AU2016236669A1 (en) 2017-09-21
AU2016236669B2 true AU2016236669B2 (en) 2018-11-08

Family

ID=56977003

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016236669A Active AU2016236669B2 (en) 2015-03-24 2016-02-01 Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof

Country Status (14)

Country Link
US (2) US10100015B2 (https=)
EP (1) EP3275867B1 (https=)
JP (1) JP6449482B2 (https=)
KR (1) KR102087918B1 (https=)
CN (3) CN106008340B (https=)
AU (1) AU2016236669B2 (https=)
CA (1) CA2980484C (https=)
IL (1) IL254098B (https=)
MX (1) MX383376B (https=)
NZ (1) NZ735044A (https=)
RU (1) RU2683566C1 (https=)
SG (1) SG11201706869XA (https=)
TW (2) TWI675026B (https=)
WO (1) WO2016150255A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016236669B2 (en) 2015-03-24 2018-11-08 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
WO2017012559A1 (zh) * 2015-07-21 2017-01-26 广州再极医药科技有限公司 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
US10829483B2 (en) * 2016-05-23 2020-11-10 Cstone Pharmaceutical (Suzhou) Co., Ltd. Thiophene, manufacturing method thereof, and pharmaceutical application of same
CN106146533B (zh) * 2016-07-14 2018-04-03 华润赛科药业有限责任公司 含硫杂环羧酸类衍生物、其制备方法和应用
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108033909A (zh) * 2017-12-20 2018-05-15 北京六合宁远科技有限公司 一种6-甲基-4-溴-异喹啉的制备方法
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111303161B (zh) * 2020-04-14 2021-01-05 遵义医科大学珠海校区 嘧啶并氮杂环类化合物及其用途
CN111763218B (zh) * 2020-07-14 2021-05-28 山东大学 一种噻吩并嘧啶酮巯乙酸类衍生物及其制备方法与应用
US20250059202A1 (en) 2022-01-04 2025-02-20 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of fused ring derivative, and preparation method therefor and use thereof
CN116465985B (zh) * 2023-03-03 2024-12-10 连云港杰瑞药业有限公司 一种气相色谱法检测α-核糖甲磺酸酯中残留溶剂的方法
EP4688750A1 (en) 2023-04-06 2026-02-11 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
CN118955327A (zh) * 2024-06-26 2024-11-15 安徽大学 一种4-溴-1-萘甲腈的合成方法
CN118878551B (zh) * 2024-07-08 2026-04-28 安徽大学 一种4-溴噻吩并[2,3-c]吡啶-2-羧酸乙酯的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103998A1 (en) * 2003-05-21 2004-12-02 Glaxo Group Limited Quinoline derivatives as phosphodiesterase inhibitors
WO2007089557A2 (en) * 2006-01-30 2007-08-09 Irm Llc Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
WO2009137404A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20130115190A1 (en) * 2011-05-05 2013-05-09 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20140005221A1 (en) * 2011-01-28 2014-01-02 Sato Pharmaceutical Co., Ltd. Ring-fused compound
CA2880178A1 (en) * 2012-07-27 2014-01-30 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558655A (en) * 1969-06-25 1971-01-26 Parke Davis & Co Benzo(b)thiopheneacetic acid compounds
US4224330A (en) 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
AUPO282896A0 (en) * 1996-10-07 1996-10-31 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
AU7031500A (en) 1999-09-23 2001-04-24 Astrazeneca Ab Therapeutic quinazoline compounds
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
ES2291981T3 (es) * 2003-11-20 2008-03-01 Eli Lilly And Company Moduladores del receptor de la vitamina d.
WO2005063828A1 (en) * 2003-12-22 2005-07-14 Basell Polyolefine Gmbh Metallocene compounds
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
GB0426313D0 (en) * 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
JPWO2007105753A1 (ja) 2006-03-16 2009-07-30 アステラス製薬株式会社 トリアゾール誘導体またはその塩
US7960567B2 (en) * 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
US8809382B2 (en) * 2009-05-04 2014-08-19 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ETE receptor antagonist compounds
TW201116281A (en) 2009-08-06 2011-05-16 Astellas Pharma Inc N atom containing ring acylguanidine derivatives
BR112012032193A2 (pt) * 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
PE20141002A1 (es) 2010-10-27 2014-08-17 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
CN104812387A (zh) * 2012-11-20 2015-07-29 霍夫曼-拉罗奇有限公司 取代的1,6-萘啶
CN105163727B (zh) * 2013-05-03 2018-08-17 豪夫迈·罗氏有限公司 刺激神经发生的异喹啉衍生物
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
BR112017013465A2 (pt) * 2014-12-24 2018-03-06 Lg Chem, Ltd derivado de biarila, e, composição farmacêutica.
AU2016236669B2 (en) 2015-03-24 2018-11-08 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103998A1 (en) * 2003-05-21 2004-12-02 Glaxo Group Limited Quinoline derivatives as phosphodiesterase inhibitors
WO2007089557A2 (en) * 2006-01-30 2007-08-09 Irm Llc Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
WO2009137404A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
WO2011150156A2 (en) * 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US20140005221A1 (en) * 2011-01-28 2014-01-02 Sato Pharmaceutical Co., Ltd. Ring-fused compound
US20130115190A1 (en) * 2011-05-05 2013-05-09 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2880178A1 (en) * 2012-07-27 2014-01-30 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NITYA G. KUNDU ET AL: "Cyclopenta[f]isoquinoline derivatives designed to bind specifically to native deoxyribonucleic acid . . . , JOURNAL OF MEDICINAL CHEMISTRY, vol. 18, no. 4, 1975-04-01, pages 395-399 *

Also Published As

Publication number Publication date
MX383376B (es) 2025-03-13
IL254098B (en) 2020-03-31
CN106008340B (zh) 2020-03-17
CN108299425B (zh) 2020-09-18
EP3275867A4 (en) 2018-01-31
CA2980484A1 (en) 2016-09-29
JP6449482B2 (ja) 2019-01-09
AU2016236669A1 (en) 2017-09-21
CN108516958B (zh) 2020-07-17
TW201641491A (zh) 2016-12-01
TW201808909A (zh) 2018-03-16
HK1226055A1 (zh) 2017-09-22
CN106008340A (zh) 2016-10-12
KR20170123705A (ko) 2017-11-08
EP3275867B1 (en) 2020-06-10
TWI666201B (zh) 2019-07-21
NZ735044A (en) 2018-10-26
CN108299425A (zh) 2018-07-20
TWI675026B (zh) 2019-10-21
EP3275867A1 (en) 2018-01-31
KR102087918B1 (ko) 2020-03-12
CN108516958A (zh) 2018-09-11
WO2016150255A1 (zh) 2016-09-29
RU2683566C1 (ru) 2019-03-29
JP2018509451A (ja) 2018-04-05
US10100016B2 (en) 2018-10-16
US20180072678A1 (en) 2018-03-15
SG11201706869XA (en) 2017-09-28
CA2980484C (en) 2019-11-26
US10100015B2 (en) 2018-10-16
MX2017012009A (es) 2018-06-06
IL254098A0 (en) 2017-10-31
US20180265476A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
AU2016236669B2 (en) Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
CN102119161B (zh) 具有β分泌酶抑制作用的含硫杂环衍生物
CN110256421A (zh) Kras-g12c抑制剂
CN111440189B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
WO2015104677A1 (en) Heterocyclic compounds as ezh2 inhibitors
TW201718561A (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
TW201605799A (zh) 溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑
CN112805005A (zh) 甲状腺素受体β促效剂化合物
CN113302183A (zh) 环脲
MX2013012520A (es) Derivado novedoso de 1-oxido de 3-hidroxi isotiazol.
WO2023202642A1 (zh) Rho相关蛋白激酶抑制剂及其制备和应用
CN114667289A (zh) 杂芳基血浆激肽释放酶抑制剂
CN112513041B (zh) 三环化合物
CN103304571B (zh) 螺环化合物、其制备方法、中间体、药物组合物和应用
TW202024020A (zh) 治療神經退化性疾病之方法
TW201934558A (zh) 苯并雜芳基類衍生物、其製備方法及其在醫藥上的應用
WO2023179078A1 (zh) 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途
TW202330472A (zh) 化合物、組合物及使用方法
HK1226055B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
WO2024160058A1 (zh) 草酸二酰胺化合物、包含其的药物组合物及其制备方法和用途
CN118546109A (zh) 含氮杂环类化合物及其医药用途
HK40029737A (en) Compounds which cause degradation of egfr, for use against cancer
HK1230186B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)